These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32199509)

  • 21. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive-behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial.
    Goodyer IM; Reynolds S; Barrett B; Byford S; Dubicka B; Hill J; Holland F; Kelvin R; Midgley N; Roberts C; Senior R; Target M; Widmer B; Wilkinson P; Fonagy P
    Health Technol Assess; 2017 Mar; 21(12):1-94. PubMed ID: 28394249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
    ; March J; Silva S; Curry J; Wells K; Fairbank J; Burns B; Domino M; Vitiello B; Severe J; Riedal K; Goldman M; Feeny N; Findling R; Stull S; Baab S; Weller EB; Robbins M; Weller RA; Jessani N; Waslick B; Sweeney M; Dublin R; Walkup J; Ginsburg G; Kastelic E; Koo H; Kratochvil C; May D; LaGrone R; Vaughan B; Albano AM; Hirsch GS; Podniesinki E; Chu A; Reincecke M; Leventhal B; Rogers G; Jacobs R; Pathak S; Wells J; Lavanier SA; Danielyan A; Rohde P; Simons A; Grimm J; Frank S; Emslie G; Kennard B; Hughes C; Mayes TL; Rosenberg D; Benazon N; Butkus M; Bartoi M
    Am J Psychiatry; 2009 Oct; 166(10):1141-9. PubMed ID: 19723787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Zhu L; Tao R; Hughes C; Croarkin P
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):21-8. PubMed ID: 22257126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment for Adolescents with Depression Study (TADS): safety results.
    Emslie G; Kratochvil C; Vitiello B; Silva S; Mayes T; McNulty S; Weller E; Waslick B; Casat C; Walkup J; Pathak S; Rohde P; Posner K; March J; ;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1440-55. PubMed ID: 17135989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
    Kennard BD; Emslie GJ; Mayes TL; Nakonezny PA; Jones JM; Foxwell AA; King J
    Am J Psychiatry; 2014 Oct; 171(10):1083-90. PubMed ID: 24935082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
    Vitiello B; Kratochvil CJ; Silva S; Curry J; Reinecke M; Pathak S; Waslick B; Hughes CW; Prentice ED; May DE; March JS
    J Am Acad Child Adolesc Psychiatry; 2007 Dec; 46(12):1642-50. PubMed ID: 18030086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
    Cerbo AD
    Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial.
    Goodyer I; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    BMJ; 2007 Jul; 335(7611):142. PubMed ID: 17556431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of treatments for adolescent depression: results from TADS.
    Domino ME; Burns BJ; Silva SG; Kratochvil CJ; Vitiello B; Reinecke MA; Mario J; March JS
    Am J Psychiatry; 2008 May; 165(5):588-96. PubMed ID: 18413703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT.
    Serfaty M; King M; Nazareth I; Moorey S; Aspden T; Tookman A; Mannix K; Gola A; Davis S; Wood J; Jones L
    Health Technol Assess; 2019 May; 23(19):1-106. PubMed ID: 31097078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
    Lewis CC; Simons AD; Nguyen LJ; Murakami JL; Reid MW; Silva SG; March JS
    J Am Acad Child Adolesc Psychiatry; 2010 Feb; 49(2):132-40. PubMed ID: 20215935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
    Kratochvil C; Emslie G; Silva S; McNulty S; Walkup J; Curry J; Reinecke M; Vitiello B; Rohde P; Feeny N; Casat C; Pathak S; Weller E; May D; Mayes T; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1412-8. PubMed ID: 17135986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
    Mayes TL; Bernstein IH; Haley CL; Kennard BD; Emslie GJ
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):513-6. PubMed ID: 21186970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
    Shamseddeen W; Clarke G; Keller MB; Wagner KD; Birmaher B; Emslie GJ; Ryan N; Asarnow JR; Porta G; Brent DA
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):29-36. PubMed ID: 22251024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
    Findling RL; McCusker E; Strawn JR
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
    [No Abstract]   [Full Text] [Related]  

  • 39. Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS).
    Jacobs RH; Reinecke MA; Gollan JK; Jordan N; Silva SG; March JS
    Behav Res Ther; 2010 Nov; 48(11):1155-9. PubMed ID: 20843506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.